Alon Bloomenfeld
Chief Executive Officer at Raziel Therapeutics RT Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Philippe Schaison | M | 62 |
Raziel Therapeutics RT Ltd.
 Raziel Therapeutics RT Ltd. Pharmaceuticals: MajorHealth Technology Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel. | 5 years |
| Yair Shamir | M | 79 |
Raziel Therapeutics RT Ltd.
Raziel Therapeutics RT Ltd. Pharmaceuticals: MajorHealth Technology Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel. | 5 years |
| Eyal Lifschitz | M | - |
Raziel Therapeutics RT Ltd.
Raziel Therapeutics RT Ltd. Pharmaceuticals: MajorHealth Technology Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel. | 5 years |
| Tomer Kariv | M | 62 |
Raziel Therapeutics RT Ltd.
Raziel Therapeutics RT Ltd. Pharmaceuticals: MajorHealth Technology Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel. | 8 years |
| Adi Goldin | M | 49 |
Raziel Therapeutics RT Ltd.
Raziel Therapeutics RT Ltd. Pharmaceuticals: MajorHealth Technology Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel. | 11 years |
| Shmuel Cabilly | M | 74 |
Raziel Therapeutics RT Ltd.
Raziel Therapeutics RT Ltd. Pharmaceuticals: MajorHealth Technology Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel. | 12 years |
| Zafrira Avnur | M | 73 |
Raziel Therapeutics RT Ltd.
Raziel Therapeutics RT Ltd. Pharmaceuticals: MajorHealth Technology Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel. | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Shmuel A. Ben-Sasson | M | - |
Raziel Therapeutics RT Ltd.
Raziel Therapeutics RT Ltd. Pharmaceuticals: MajorHealth Technology Raziel Therapeutics RT Ltd. develops innovative technology to treat obesity disease. It is developing RZL-12, is a potential first-in-class, injectable drug for the reduction of fat cell mass. the firm developed a novel drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into brown adipose tissue-like. The company was founded by Shmuel A. Ben-Sasson in 2012 and is headquartered in Jerusalem, Israel. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Israel | 8 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alon Bloomenfeld
- Personal Network
